|
Genomic classifier to augment the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model. |
|
|
|
Consulting or Advisory Role - GenomeDx |
Travel, Accommodations, Expenses - GenomeDx |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Travel, Accommodations, Expenses - GenomeDx |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - GenomeDx |
Consulting or Advisory Role - Healthtronics |
Research Funding - metamark genetics |
|
|
Consulting or Advisory Role - GenomeDx |
|
Research Funding - GenomeDx; Medivation/Astellas |
Travel, Accommodations, Expenses - GenomeDx |
|
|
Stock and Other Ownership Interests - Armune Bioscience; Parallel6 |
Consulting or Advisory Role - Armune Bioscience; Astellas Pharma; Bayer; Dendreon; GenomeDx; Janssen Biotech; MDxHealth; Medivation; Parallel6; Sanofi |
Speakers' Bureau - Dendreon |
Research Funding - Amgen (Inst); Bayer (Inst); Dendreon (Inst); GenomeDx (Inst); Janssen Biotech (Inst); Metabolon (Inst); Mitomics (Inst); Myriad Genetics (Inst); POM Wonderful (Inst); Progenika (Inst) |
Travel, Accommodations, Expenses - GenomeDx; Myriad Genetics; Sanofi |
|
|
Consulting or Advisory Role - GenomeDx; Myriad Genetics |
|
|
Consulting or Advisory Role - GenomeDx; Glenview COnsulting; Johnson & Johnson; Merck KGaA |
|
Travel, Accommodations, Expenses - Bayer; Merck KGaA; Varian Medical Systems; Vertex |
Other Relationship - Department of Defense-Prostate Cancer Research Program; NRG Oncology |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - GenomeDx |
Patents, Royalties, Other Intellectual Property - CANCER DIAGNOSTICS USING BIOMARKERS 20140066323 |
Travel, Accommodations, Expenses - GenomeDx |
|
|
No Relationships to Disclose |